123 related articles for article (PubMed ID: 38595134)
1. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease.
Petrov JC; Al-Bawardy B; Alzahrani R; Mohamed G; Fine S
J Clin Gastroenterol; 2024 Apr; ():. PubMed ID: 38595134
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease.
Petrov J; Fine S; Alzahrani R; Mohamed G; Al-Bawardy B
J Clin Gastroenterol; 2024 Feb; ():. PubMed ID: 38300529
[TBL] [Abstract][Full Text] [Related]
3. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
4. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
Yerushalmy-Feler A; Pujol-Muncunill G; Martin-de-Carpi J; Kolho KL; Levine A; Olbjørn C; Granot M; Bramuzzo M; Rolandsdotter H; Mouratidou N; Hradsky O; Scarallo L; Matar M; Rimon RM; Rinawi F; Shalem T; Najajra H; de Meij T; Aloi M; Rodríguez-Belvís MV; Alvisi P; Schneider AM; van Rheenen P; Navas-López VM; Kiparissi F; Barrio J; Turner D; Cohen S
J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):717-723. PubMed ID: 36084231
[TBL] [Abstract][Full Text] [Related]
5. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab dose escalation improves clinical responses in refractory Crohn's disease.
Haider SA; Yadav A; Perry C; Su L; Akanbi O; Kudaravalli P; Tripathi N; Hashim MA; Abdelsalam M; Hussein M; Elkheshen A; Patel V; Ali SE; Lamb L; Ingram K; Mayne C; Stuffelbeam AB; Flomenhoft D; Stromberg A; Barrett TA
Therap Adv Gastroenterol; 2020; 13():1756284820959245. PubMed ID: 33133239
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
[TBL] [Abstract][Full Text] [Related]
8. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
Johnson AM; Barsky M; Ahmed W; Zullow S; Galati J; Jairath V; Narula N; Peerani F; Click BH; Coburn ES; Dang TT; Gold S; Agrawal M; Garg R; Aggarwal M; Mohammad D; Halloran B; Kochhar GS; Todorowski H; Ud Din NM; Izanec J; Teeple A; Gasink C; Muser E; Ding Z; Swaminath A; Lakhani K; Hogan D; Datta S; Ungaro RC; Boland BS; Bohm M; Fischer M; Sagi S; Afzali A; Ullman T; Lawlor G; Baumgart DC; Chang S; Hudesman D; Lukin D; Scherl EJ; Colombel JF; Sands BE; Siegel CA; Regueiro M; Sandborn WJ; Bruining D; Kane S; Loftus EV; Dulai PS
Am J Gastroenterol; 2023 Feb; 118(2):317-328. PubMed ID: 36191274
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.
Lim CT; Tay SW; Elangovan S; Ong WC; Lim GH; Salazar E; Chan WPW; Tan MTK
J Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38680014
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response.
Heron V; Li Fraine S; Panaccione N; Restellini S; Germain P; Candido K; Bernstein CN; Bessissow T; Bitton A; Chauhan UK; Lakatos PL; Marshall JK; Michetti P; Seow CH; Rosenfeld G; Panaccione R; Afif W
J Can Assoc Gastroenterol; 2022 Oct; 5(5):208-213. PubMed ID: 36196277
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
Ahmed Z; Venkata K; Zhang N; Malik TA
Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
[TBL] [Abstract][Full Text] [Related]
16. [Analysis on the efficacy of dual vein induction therapy of Ustekinumab in complex perianal fistulizing Crohn's disease].
Zhang DL; Shao XX; Hu DY; Lin DP; Wu H; Jiang Y
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(41):3301-3306. PubMed ID: 37926575
[No Abstract] [Full Text] [Related]
17. Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China.
Li P; Wang L; Tang Z; Wang Y; Liu Z; Ge W; Huang Y
Front Pediatr; 2024; 12():1371322. PubMed ID: 38665375
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE).
Eberl A; Hallinen T; Af Björkesten CG; Heikkinen M; Hirsi E; Kellokumpu M; Koskinen I; Moilanen V; Nielsen C; Nuutinen H; Suhonen UM; Utriainen K; Vihriälä I; Soini E; Wennerström C; Nissinen R; Borsi A; Koivunen M; Tillonen J; Sipponen T
Scand J Gastroenterol; 2019 Jun; 54(6):718-725. PubMed ID: 31184512
[No Abstract] [Full Text] [Related]
19. Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.
Hirayama H; Morita Y; Imai T; Takahashi K; Yoshida A; Bamba S; Inatomi O; Andoh A
BMC Gastroenterol; 2022 Apr; 22(1):195. PubMed ID: 35448957
[TBL] [Abstract][Full Text] [Related]
20. Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease.
Derikx LAAP; Plevris N; Su S; Gros B; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW
Dig Liver Dis; 2023 Aug; 55(8):1034-1041. PubMed ID: 36283944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
